On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
The new online Learning Center with new content can still be found under the “Training” folder on ...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...